当前位置:首页 >财报库 > 报告详情

默沙东Merck & Co. Inc.(MRK)2025年第三季度财报(10-Q)「NYSE」(英文版)(53页).pdf

上传人: 1****1 编号:987245 2025-12-09 53页 548.89KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30,2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 19

2、34For the transition period from _ to _Commission File No.1-6571 Merck&Co.,Inc.(Exact name of registrant as specified in its charter)New Jersey22-1918501(State or other jurisdiction of incorporation)(I.R.S.Employer Identification No.)126 East Lincoln AvenueRahwayNew Jersey07065(Address of principal

3、executive offices)(zip code)(Registrants telephone number,including area code)(908)740-4000 Not Applicable(Former name,former address and former fiscal year,if changed since last report.)Securities Registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchan

4、ge on which registeredCommon Stock($0.50 par value)MRKNew York Stock Exchange1.875%Notes due 2026MRK/26New York Stock Exchange3.250%Notes due 2032MRK/32New York Stock Exchange2.500%Notes due 2034MRK/34New York Stock Exchange1.375%Notes due 2036MRK 36ANew York Stock Exchange3.500%Notes due 2037MRK/37

5、New York Stock Exchange3.700%Notes due 2044MRK/44New York Stock Exchange3.750%Notes due 2054MRK/54New York Stock ExchangeIndicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 mo

6、nths(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursua

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,以下是Merck & Co., Inc. 2025年第三季度报告的简要概括: 1. **财务表现**:2025年第三季度收入为172.76亿美元,同比增长5.2%;净收入为57.85亿美元,同比增长82.6%。 2. **研发和收购**:Merck持续进行研发和收购,包括收购Verona Pharma和与Blackstone Life Sciences的合作,以支持其产品管线。 3. **合作安排**:与AstraZeneca、Eisai、Bayer、Ridgeback Biotherapeutics LP、Daiichi Sankyo和Moderna等公司有合作研发和商业化协议。 4. **重组计划**:实施2025年重组计划,预计将节省约30亿美元,大部分为现金支出,主要用于员工遣散费和合同终止费用。 5. **财务状况**:截至2025年9月30日,现金及现金等价物为181.69亿美元,较年初增长37.2%。
** 财富增长,Merck如何? ** Merck合作布局,揭秘! ** Merck重组计划,未来展望?
客服
商务合作
小程序
服务号
折叠